(Q43520925)

English

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 November 2017

The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study (English)

1 reference

Europe PubMed Central

24 November 2017

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

D Paolicelli

1

1 reference

Europe PubMed Central

24 November 2017

M D'Onghia

2

1 reference

Europe PubMed Central

24 November 2017

F Pellegrini

3

1 reference

Europe PubMed Central

24 November 2017

V Direnzo

4

1 reference

Europe PubMed Central

24 November 2017

P Iaffaldano

5

1 reference

Europe PubMed Central

24 November 2017

V Lavolpe

6

1 reference

Europe PubMed Central

24 November 2017

M Trojano

7

1 reference

Europe PubMed Central

24 November 2017

publication date

17 February 2013

1 reference

Europe PubMed Central

24 November 2017

Journal of Neurology

1 reference

Europe PubMed Central

24 November 2017

260

1 reference

Europe PubMed Central

24 November 2017

6

1 reference

Europe PubMed Central

24 November 2017

1562-1568

1 reference

Europe PubMed Central

24 November 2017

https://scigraph.springernature.com/pub.10.1007/s00415-012-6829-3

0 references

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

A sensitive antiviral neutralization bioassay for measuring antibodies to interferons

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

The central role of the propensity score in observational studies for causal effects

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6829-3

21 January 2018

Quantitation of neutralization of interferon by antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statistical issues in neutralizing antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23417273

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-012-6829-3

1 reference

Europe PubMed Central

24 November 2017

1 reference

Europe PubMed Central

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43520925&oldid=1990499850"